FY2025 EPS Estimates for TSE:ONC Raised by Leede Financial

Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Leede Financial lifted their FY2025 EPS estimates for shares of Oncolytics Biotech in a research note issued on Monday, March 10th. Leede Financial analyst D. Loe now forecasts that the company will post earnings of ($0.40) per share for the year, up from their prior estimate of ($0.41). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech's FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at ($0.13) EPS.

Oncolytics Biotech Price Performance

TSE:ONC remained flat at C$0.91 on Thursday. The company's stock had a trading volume of 28,900 shares, compared to its average volume of 123,307. The business has a 50-day moving average price of C$1.09 and a 200-day moving average price of C$1.30. The stock has a market cap of C$70.14 million, a PE ratio of -2.54 and a beta of 1.35. Oncolytics Biotech has a fifty-two week low of C$0.86 and a fifty-two week high of C$2.08. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.